Today: 7 February 2026
Subscribe
Browse Category

CSE:BO News 19 August 2025

Luxury Wireless Headphones Showdown: B&O H95 vs B&W PX8 vs Focal Bathys – Which Reigns Supreme?

Luxury Wireless Headphones Showdown: B&O H95 vs B&W PX8 vs Focal Bathys – Which Reigns Supreme?

The Beoplay H95 (2020), PX8 (2022), and Bathys (2022) are the flagship wireless headphones from Bang & Olufsen, Bowers & Wilkins, and Focal. Beoplay H95 delivers up to 38 hours of playback with ANC on (50 hours with ANC off). PX8 provides about 30 hours of playback with ANC on, with a 15-minute charge yielding about 7 hours. Bathys offers roughly 30 hours of Bluetooth ANC playback, 35 hours via 3.5 mm, and up to 42 hours in USB-DAC mode. Bathys supports USB-C DAC mode delivering up to 24-bit/192 kHz audio. Beoplay H95 features adaptive ANC with five levels controlled
19 August 2025

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop